Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...

Biogen has said it hopes new “real world” data will ensure patients are not put off taking its key multiple sclerosis drug, Tecfidera because of stomach problems that can occur early in treatment.

Sales of Biogen’s MS drugs like Tecfidera and Tysabri are likely to have declined amid rising competitive pressure in the market. Tecfidera sales have been declining as multiple generic versions ...

Biogen generated nearly $6 billion in MS revenue in 2023, although we see these sales declining nearly 10% annually as the firm faces branded competition, generic pressure on Tecfidera ...